




References



References

- Abramov, Y.; Elchalal, U.; Schenker, J.G. (1999) :*
Obstetric outcome of in vitro fertilization pregnancies complicated by severe hyperstimulation syndrome : A multicentre study
Fertil. Steril; 70:1070-1076.
- Acién, P.; Mauri, M.; Gutierrez, M. (1997):* Clinical and hormonal effects of the combination gonadotropin releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease related hyperandrogenism.
Hum. Reprod., 12:423.
- Adams, J.; Polson, D.W. and Franks, S. (1986):*
Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. *British Medical Journal*; 293:355-359.
- Albano, C.; Smitz, J.; Camus, M.; Riethmuller-Winzen, H.; Siebert-Weigel, M.; Diedrich, K.; Van Steirteghem, A.C. and Devroey, P. (1996):* Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal



References



gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix). Hum. Reprod., 11, 2114-2118.

Albuquerque, L.E.; Saconato, H.; maciel, M.C.; Baracat, E.C.; Freitas, V. (2003): Depot versus daily administration of GnRH agonist protocols for pituitary desensitization in assisted reproduction cycles: a Chochrane Review. Hum. Reprod., 18:2008.

American Society for Reproductive Medicine (2000): Effectiveness and treatment for unexplained infertility. A practice committee report, Birmingham., AL.

Ashton, W.E. (1906): Textbook on the practice of gynecology for practitioners and students Philadelphia, W.B.; Saunders, Ends. 2.

Asuncion, M.; Calvo, R.M. San Millan, J.L.; Sancho, J.; Avila, S.; Escobar-Morreale, H.F. (2000): A prospective study of prevalence of the polycystic ovary syndrome in unselected caucasian women from Spain. J. Clin. Endocrinol. Metabl., 85:2434-8.

Attia, G.R.; Rainey, W.E.; Carr, B.R. (2001): Metformin directly inhibits androgen



production in human thecal cells. *Fertil. Steril.*, 76:517-524.

- Azziz, R.; Ehrmann, D.; Legro, R.S.; Whitcomb, R.W.; Hanley, R.; Fereshetian, A.G.; O'Keefe, M.; Ghazzi, M.N. (2001): PCOS/ Troglitazone Study Group, Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. *J. Clin. Endocrinol. Metab.*, 86:1626.
- Badawy, A.; State, O.; Abdelgawad, S. (2007): N - Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial. *Acta Obstet Gynecol Scand.*; 86(2):218-22.
- Baillargeon, J.P.; Iuorno, M.J.; Nestler, J.E. (2003): Insulin sensitizers for polycystic ovary syndrome. *Clin Obstet Gynecol.*, 46:325-40.
- Balasch, J.; Fabregues, F.; Creus, M.; Casamitjana, R.; Puerto, B. and Vanrell, J. A. (2000): Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: A prospective, randomized trial of two starting doses in a chronic low-dose



step-up protocol. J. Assist. Reprod. Genet., 17, 561-565.

Balasch, J.; Fabregues, F.; Creus, M.; Puerto, B.; Penarrubia, J. and Vanrell, J.A. (2001) : Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovary syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Hum. Reprod., 16, 652-656.

Baldwin, D.M. and Sawyer, C. (1989): Effect of dexamethasone on LH release and ovulation in the cystic rat. J. Clin. Endocrinol. Metab., 94:1397.

Banaszewska, B.; Pawelczyk, L.; Spaczynski, R.Z.; Dziura, J.; Duleba, A.J. (2007): Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab. Feb;92(2):456-61.

Barbier, R.L. (2001) : The initial fertility consultation: Recommendations concerning cigarette smoking, body mass index and alcohol and



caffeine consumption. Am. J. Obstet. Gynecol., 185:1168-73.

Batukan, C. and Baysal, B. (2001): Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. Arch. Gynecol. Obstet., 265:124-7.

Bidzeniska, B.; Tworowska, U.; Demissie, M.; Milewicz, A. (2000): Modified dexamethasone and gonadotropin releasing hormone-agonist (Dexa-GnRha) test in the evaluation of androgen source in hirsute women. Przegl. Lek., 57:393-6.

Boostanfar, R.; Jain, J.K.; Mishell, D.R. Jr., Paulson, R.J. (2001): A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil. Steril., 75:1024.

Boostanfar, R.; Jain, J.K.; Mishell, D.R.; Jr., Paulson, R.J. (2004): Prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil. Steril., 75:305.

Braat, D.D.; Ayalon, D.; Blunt, S.M.; Bogchelman, D.; Coelingh Bennink, H.J.; Handelsman,



References



- D.J.; Heineman, M.J; Lappobn, R.E.; Lorijn, R.H.; Rolland, R. et al. (1989):* Pregnancy outcome in luteinizing hormone releasing hormone induced cycles : a multicentre study. *Gynecol. Endocrinol.*, 3:35.
- Branigan, E.F.; Estes. M.A. (2003):* A randomized clinical trial of treatment of clomiphene citrate resistant anovulation with the use of oral contraceptive pill suppression and repeat clomiphene citrate treatment. *Am. J. Obstet. Gynecol.*, 188:1424.
- Brann, D. and Mahesh, V.(1991):* Role of corticosteroids in reproduction. *FASEB*, 5:2691-8.
- Brann, D.; O'Conner, J.; Wade, M.; Mashesh, V. (1992):* LH and FSH subunit mRNA concentration during the progesterone-induced gonadotropin surge in ovariectomized estrogen-primed immature rats. *Mol. Cells Neurosci.*, 3:171-8.
- Bray, G.A.; Blackburn, G.L.; Ferguson, J.M.; Greenway, F.L.; Jain, A.K.; Mendel, C.M.; Mendels, J.; Ryan, D.H.; Schwartz, S.L.; Scheinbaum, M.L.; Seaton, T.B. (1999):* Sibutramine produces dose related weight loss, *Obes. Res.*, 7:189.



- Bryan, E. (2003):* The impact of multiple preterm births on the family. *Br. J. Obstet. Gynaecol.*, 110 (suppl 20) : 24.
- Burkman, R.T.; Tang, M.T.; Malone, K.E.; Marchbanks, P.A.; McDonald, J.A.; Folger, S.G.; Norman, S.A.; Strom, B.L.; Berustein, L.; Ursin, G.; Weiss, L.K.; Daling, J.R.; Slmon, M.S.; Spirtas, R. (2003):* Infertility drugs and the risk of breast cancer. findings from the National Institute of Child Health and Human Development Women's Contraceptive and reproductive experiences study. *Fertil. Steril.*, 79:844.
- Carmina, E. and Lobo, R.A.(1999):* Do hyperandrogenic women with normal menses have polycystic ovary syndrome? *Fertility and Sterility*; 71:319-322.
- Carmina, E.; Koyama, T.; Chang, T.; Stanczyk, F.Z.; Lobo, R.A. (1992):* Does ethnicity influence the prevbalaence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. *Am. J. Obstet. Gynecol.*, 167:1807.



References



- Castello, M.E. and Eden, J.A. (2003):* A systemic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. *Fertil. Steril.*, 79:1-13.
- Cedars, M.I.; Surey, E.; Hamilton, F.; Lapolt, P. and Meldrum, D.R. (2005):* Leuprolide acetate lower circulating bioactive luteinizing hormone and testosterone concretions during ovaries stimulation for oocyte retrieval. *Fertil. Steril.*, 63:627.
- Centers for Disease Control and Prevention (2000):* Contribution of assisted reproductive technology and ovulation inducing drugs to triplet and higher order multiple births. United States., 1980-97, *MMWR*, 49:535.
- Cheang, K.I.; Sharma, S.T.; Nestler, J.E. (2006):* Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? *Gynecol Endocrinol.* Nov;22(11):595-604.
- Cibula, D.; Skrha, J.; Hill, M.; Fanta, M.; Haakova, L.; Vrbikova, J.; Zivny, J. (2002):* Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.*, 87:5821-2825.



References



- Coelingh Bennink, H.J.; Fauser, B.C. and Out, H.J. (1998):* Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group. *Fertil. Steril.*, 69, 19-25.
- Conway, G.S. and Honour, J.W. (1990):* Heterogeneity of the PCOS/clinical endo-crine and ultrasound features in 556 patients. *Clin. Endocrinol.*, 33: 593-603.
- Costello, M.F.; Shrestha, B; Eden, J.; Johnson, N.P.; Sjoblom, P. (2007):* Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. *Hum Reprod.* May;22(5):1200-9.
- Dahlgren, E.; Landin, K.; Krotkiewski, M.; Holm, G.; Janson, P.O. (1998) :* Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. *Hum. Reprod.*, 13:2706-11.



- De Leo, V.; La Marca, A.; Petraglia, F. (2003):*
Insulin-lowering agents in the management of
polycystic ovary syndrome. *Endocr. Rev.*,
24:633-667.
- De Leo, V.; la Marca, A.; Ditto, A.; Morgante, G.;
Cianci, A. (1999):* Effects of metofrmin on
gonadotropin-induced ovulation in women with
polycystic ovary syndrome. *Fertil. Steril.*,
72:282-5.
- De Leo, V.; la Marca, A.; Pertraglia, F. (2003):*
Insulin-lowering agents in the management of
polycystic ovary syndrome. *Endocr. Rev.*,
24:633-667.
- deLeeuw, R.; Mulders, J.; Voortman, G.; Rombout,
F.; Damm, J. and Kloosterboer, L.
(1996):*Structure-function relationship of
recombinant follicle stimulating hormone
(Puregon). *Mol. Hum. Reprod.*, 2:361-369.
- Devane, G.W.; Czekala, N.M.; Hudd, H.L. and Yen,
S.S.C. (1975):* Circulating gonadotropins,
estrogens and androgens in polycystic ovarian
disease. *Am. J. Obstet. Gynecol.*, 121:496.
Quoted from: Soule, S.G. (1996) neuroendo-
crinology of the polycystic ovary syndrome,



Baillieres Clin. Endocrinol. Metab., 10(2):205-19.

Diamanti-Kandarakis, E.; Baillargeon, J.P.; Iuorno, M.J.; Jakubowicz, D.J.; Nestler, J.E. (2003) : A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J. Clin. Endocrinol. Metab., 88:1927-32.

Dickey, R.P.; Taylor, S.N.; Curole, D.N.; Rye, P.H.; Pyrzak, R. (1996): Incidence of spontaneous abortion in clomiphene pregnancies. Hum. Reprod., 11:2623.

Ecochard, R.; Marret, H.; Rabilloud, M.; Bradal, R.; Boehringer, H.; Girotto, S.; Barbato, M. (2000): Sensitivity and specificity of ultrasound indices of ovulation in spontaneous cycles. Eur. J. Obstet. Gynecol. Reprod. Biol., 91:59.

Edwards, A.; Trrot, L.; Plouffe, J.R.; Kieth, H.; Randall, H.; Darrel, W.; et al. (1996): Ovulation induction in clomiphene-resistant anovulatory women with normal DHEAS levels: beneficial effects the addition of dexamethasone during the follicular phase. Fertil. Steril., 66:3 484-6.



- Ehrmann, D.A.; Barnes, R.B.; Rosenfield, R.L. (1995):* Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. *Endocr. Rev.*, 16:322.
- El-Tabbakh, G.H.; Lotfy, I.; Azab, L.; Rahman, H.; Southern, A. and Aleem, F. (1986):* Correlation of the ultrasonic appearance of the ovaries in polycystic of the ultrasonic appearance of the ovaries in polycystic ovarian disease and the clinical hormonal and in polycystic ovarian disease and the clinical hormonal and laparoscopic findings *Am. J. Obstetrics and Gynecology.*, 154:892-5.
- Elkind-Hirsch, K.E.; Valdes, C.T.; McConnell, T.G.; Malinak, L.R. (1991):* Androgen responses to acutely increased endogenous insulin levels in hyperandrogenic and normal cycling women. *Fertil. Steril.*, 55:486.
- Elter, K.; Imir, G.; Durmusoglu, F. (2002):* Clinical endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovary syndrome: a randomized controlled study. *Human Reprod.*, 17:1729-37.



ESHERE Capri Workshop Group (2000): Multiple gestation pregnancy, Hum Reprod., 15:1856.

Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (2001): Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III), JAMA.; 285:2485.

Facchini, F.S.; Hua, N.; Abbasi, F.; Reaven, G.M. (2001): Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab., 86:3574.

Factor, S.A. (1999): Dopamine agonists, Med. Clin. North. Am., 83:415.

Field, A.E.; Coakley, E.H.; Must, A.; Spadano, J.L.; Laird, N.; Dietz, W.H.; Rimm, E.; Colditz, G.A. (2001): Impact of over weight on the risk of developing common chronic diseases during a 10 year period. Arch. Intern. Med., 161:1581.



- Filicori, M.; Cognigni, G.E.; Pocognoli, P.; Tubarelli, C.; Ferlini, F.; Perri, T.; Parmegiani, L. (2003):* Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. *Fertil. Steril.*, 80:390.
- Fisher, S.A.; Reid, R.L.; Van Vugt, D.A.; Casper, R.F. (2002):* A randomized double blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. *Fertil. Steril.*, 78:280.
- Fleming, R.; Hopkinson, Z.E.; Wallace, A.M.; Greer, I.A. (2002):* Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo controlled trial. *J. Clin. Endocrinol. Metab.*, 87:569-74.
- Fonseca, V.A.; Valiquett, T.R.; Huang, S.M.; Ghazzi, M.N.; Whitcomb, R.W. (1998):* Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized controlled study. *J. Clin. Endocrinol. Metab.*, 83:3169-76.



References



- Ford, E.S.; Giles, W.H.; Dietz, W.H. (2002):* Prevalence of the metabolic syndrome among U.S. adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA, 287:356.
- Foster, G.D.; Wyatt, H.R.; Hill, J.O.; McGuckin, B.G.; Brill, C.; Mohammed, B.S.; Szapary, P.O.; Rader, D.J.; Edman, J.S.; Klein, S. (2003):* A randomized trial of a low carbohydrate diet for obesity. New Engl. J. Med., 348:2082.
- Fremark, M.; Bursey, D. (2001):* The effect of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics, 107:E55.
- Gambineri, A.; Patton, L.; Vaccina, A.; Cacciari, M.; Morselli-Labate, AM.; Cavazza, C.; Pagotto, U.; Pasquali, R. (2006):* Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab. Oct; 91 (10): 3970-80.



- Garrow, J.S. (1992):* Treatment of obesity. *Lancet.*, 340:409.
- Genazzani, A.D.; Battaglia, C.; Gamba, O.; Petraglia, F.; Malavasi, B.; Genazzani, A.R. (2000):* The use of a combined regimen of GnRH agonist plus a low dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycystic ovary disease after discontinuation of treatment. *J. Assist. Reprod. Genet.*, 17:269.
- Gerli, S.; Gholami, H.; Manna, A.; Difrega, A.S.; Vitiello, C.; Unfer, V. (2000):* Use of ethinyl estradiol to reverse the antiestrogenic effects of CC in patients undergoing intrauterine insemination; a comparative randomized study. *Fertil. Steril.*, 73:85–89.
- Geva, E.; Jaffe, R.B. (2000):* Role of vascular endothelial growth factor in ovarian physiology and pathology. *Fertil. Steril.*, 74:429.
- Ghazeeri, G.; Kutteh, W.H.; Bryer-Ash, M.; Haas, D.; Ke, R.W. (2003):* Effect of rosiglitazone on spontaneous and clomiphene citrate induced



ovulation in women with polycystic ovary syndrome. *Fertil. Steril.*, 79:562.

Gill, S.; Taylor, A.E.; Martin, K.A.; Welt, C.K.; Adams, J.M.; Hall, J.E. (2001): Specific factors predict the response to pulsatile gonadotropin releasing hormone therapy in polycystic ovarian syndrome. *J. Clin. Endocrinol. Metab.*, 86:2428.

Gleicher, N.; Oleske, D.M.; Tur-Kaspa, I.; Vidall, A.; Karande, V. (2000): Reducing the risk of high order multiple pregnancy after ovarian stimulation with gonadotropins. *New Engl. J. Med.*, 343:2.

Glintborg, D.; Hermann, A.P.; Andersen, M.; Hagen, C.; Beck-Nielsen, H.; Veldhuis, J.D.; Henriksen, J.E. (2006): Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. *Fertil Steril.* 2006 Aug;86(2):385-97.

Glintborg, D.; Stiliving, R.K.; Hagen, C.; Hermann, A.P.; Erystyk, J.; Veldhuis, J.D.; Flyvbjerg, A.; Anderesen, M. (2005): Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated



GH levels in polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 90(10):5605-12.

Glueck, C.J.; Moreira, A.; Goldenberg, N.; Slev, L.; Wang, P. (2003): Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum. Reprod., 18:1618.

Glueck, C.J.; Philips, H.; Cameron, D.; Sieve-Smith, L.; Wang, P. (2001b) : Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: A pilot study. Fertil. Steril., 75:46-52.

Glueck, C.J.; Wang, P.; Fontaine, R.; Tracy, T.; Sieve-Smith, L. (1999): Metformin induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism, 48:511-9.

Glueck, C.J.; Wang, P.; Fontaine, R.; Tracy, T.; Sieve-Smith, L. (2001a): Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome. J. Adolesc. Health., 29:160-9.



- Glueck, C.J.; Wang, P.; Kobayashi, S.; Phillips, H.; Sieve-Smith, L. (2002a):* Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. *Fertil. Steril.*, 77:520-5.
- Gokcel, A.; Gumurdulu, Y.; Karaköse, H.; Melek Ertorere, E.; Tanaci, N.; Bascil Tutuncu, N. et al. (2002b):* Evaluation of the safety and efficacy of sibutramine, orlistate and metformin in the treatment of obesity. *Diabetes Obes. Metabl.*, 4:49-55.
- Grahma, D.J.; Green, L.; Senlor, J.R.; Nourjah, P. (2003):* Troglitazone induced liver failure : a case study, *Am. J. Med.*, 114:299.
- Griesinger, G.; Diedrich, K.; Tarlatzis, B.C.; Kolibianakis, E.M. (2006):* GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. *Reprod Biomed Online*. Nov;13(5):628-38.
- Grochowski, D.; Wolezynski, S.; Kuczynski, W.; Domitrz, J.; Szamatowlal, Szamatowlez, M. (2001):* Correctly timed coasting reduces



the risk of ovarian hyper stimulation syndrome and gives good cycle outcome in an in fertil. program. *Gynecol. Endocrinol.*, 15:234.

Guido, M.; Romualdi, D.; Giuliani, M.; Suriano, R.; Tienforti, D.; Costantini, B.; Lanzone, A. (2005): Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome. *Fertil. Steril.*, 84(5):1470-6.

Hall, J.G. (2003): Twinning. *Lancet.*, 362:735.

Hamilton-Fairley, D., Kiddy, D., Watson, H., Sagle, M. and Franks, S. (1991): Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. *Hum. Reprod.*, 6, 1095-1099.

Haning, R.V. Jr; Austin, C.W.; Carlson, I.H.; Kuzma, D.; Zweibel, W.J. (1985): Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis. *Obstet. Gynecol.*, 65:299 –305.

Haritha, S.; Rajagopalan, G. (2003): Follicular growth, endometrial thickness and serum estradiol levels in spontaneous and clomiphene citrate



induced cycles. *Int. J. Gynaecol. Obstet.*, 81:287.

Hayden, C.J.; Balen, A.H. and Rutherford, A.J. (1999): Recombinant gonadotrophins. *Br. J. Obstet. Gynaecol.*, 106, 188-196.

Hedon, B.; Hugues, J.N.; Emperaire, J.C.; Chabaud, J.J.; Barbereau, D.; Boujenah, A.; Howles, C.M. and Truong, F. (1998): A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. *Hum. Reprod.*, 13, 2688-2692.

Homburg, R. and Arnor, N.A. (1998): Influence of serum LH concentrations on ovulation; conception and early pregnancy loss in PCOS. *BMJ*, 97:1024 -6.

Homburg, R. and Howles, C.M. (1999): Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements [published erratum appears in *Hum. Reprod. Update* 2000, 6, 106]. *Hum. Reprod. Update*, 5, 493-499.



References



- Howles, C.M. (1996):* Genetic engineering of human FSH (Gonal-F). Hum. Reprod. Update, 2, 172-191.
- Huber-Buchholz, M.M.; Darey, D.G.; Norman, R.J. (1999):* Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone. J. Clin. Endocrinol. Metab., 84:1470-4.
- Hughes, E.; Collins, J. and Vandekerckhove, P. (2000):* Gonadotrophin- releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome (Cochrane Review). The Cochrane Library, Issue 2. Update Software, Oxford.
- Hull, M.G.R. (1987):* Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecology Endocrinol., 1, 235-245.
- Ibanez, K.; Valls, C.; Potau, N.; Marcos, M.V. de Zehner, F. (2000):* Sensitization of insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinemia after precocious pubarche. J. Clin. Endocrinol Metab., 85:3526-30.



- Ibanez, L.; Valls, C.; Ferrer, A.; Marcos, V.; Rodriguez-Hierro, F.; de Zegher, F. (2001):* Sensitization to insulin induces ovulation in non obese adolescents with anovulatory hyperandrogenism. *J. Clin. Endocrinol. Metab.*, 86:3595-8.
- Ibáñez, L. and Zegher, F. (2003):* Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. *Human Reprod.*, 18:57-60.
- Imani, B.; Eijkemans, M.J.; Velde, E.R.; Habbema, J.D.; Fauser, B.C. (2002):* A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrhetic infertility. *Fertil. Steril.*, 77:91.
- Ingmann, L.; Siano, L.; Schmidt, D.; Nulsen, J.; Maier, D.; Benadiva, C. (2006):* GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. *Reprod Biomed Online*. Nov;13(5):639-44.
- Jakicic, J.M.; Marous, B.H.; Gallagher, K.I.; Napotitano, M.; Lang, W. (2003):* Effect



References



of exercise duration and intensity on weight loss in overweight, sedentary women, JAMA, 290:1323.

Jakubowicz, D.J.; Iuorno, M.J.; Jakubowicz, S.; Roberts, K.A.; Nestler, J.E. (2002) : Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 87:524–9.

Jansen, C.; Tucker, K. (2003): Microdose GnRh for the stimulation of lower responders. Art and Science of Assisted Reproductive Techniques, 12:73-77.

Kaltsas, G.A.; Korbonits, M.; Isidori, M.A.; Webb, J.A.; Trannar, P.J.; Monson, J.P. et al. (2000): How common are polycystic ovaries and the polycystic ovarian syndrome in women with cushing's syndrome. Clin. Endocrinol. (Oxf), 53:493–500.

Karacan, M.; Imani, B.; Eijkemas, M.J.; Te Velde, E.R.; Habbema, J.D. and Fauser, B.D. (2002): A monogram to predict the probability of live birth after induction of ovulation with GnRH agonist short protocol. Fertil. Steril., 77:91.



- Karancle, N.; Barbieri, R.L.; Hornstein, M.D. (2005):* Assisted reproductive technique IVF success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with GnRH analogues. *Endocr. Rev.*, 20:249-252.
- Keay, S.D., Jenkins, J.M. (2003):* Adjunctive use of dexamethasone in clomid resistant patients. *Fertil. Steril.*, 80:230.
- Kelestimur, F. and Sahin, Y. (1998):* Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. *Fertil. Steril.*, 69:66-69.
- Kelestimur, F.; Unluhizarci, K.; Bayram, F.; Sahin, Y.; Tutus, A. (2000):* Metformin and polycystic ovary syndrome. *Clin Endocrinol (Oxf)*, 52:244 –6.
- Kelly, C.J. and Gordon, D. (2002):* The effect of metformin on hirsutism in polycystic ovary syndrome. *Eur. J. Endocrinol.*, 147:217-221.
- Kelly, J.I. and Adashi, E.Y. (1987):* ovulation induction. *Obste. Gynecol. Clin. North. Am.*, 14:831.



References



- Khattab, S.; Mohsen, I.A.; Foutouh, I.A.; Ramadan, A.; Moaz, M.; Al-Inany, H. (2006):* Metformin reduces abortion in pregnant women with polycystic ovary syndrome. *Gynecol Endocrinol.* Dec;22(12):680-4.
- Kirpichnikov, D.; McFarlane, S.; Sowers, J. (2002):* Metformin: an update. *Ann. Int. Med.*, 137:25-33.
- Knochenhauer, E.S.; Key, T.J.; Kahsar-Miller, M. et al. (1998):* Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. *Journal of Clinical Endocrinology and Metabolism*; 83:3078-3082.
- Kocak, M.; Caliskan, E.; Simsir, C.; Haberal, A. (2002):* A metformin therapy improves ovulatory rates, cervical scores and pregnancy rates in clomiphene resistant women with polycystic ovary syndrome. *Fertil. Steril.*, 77:101-5.
- Korytkowski, M.T.; Mogan, M.; Horwitz, M.J.; Berga, S.L. (1995):* Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.*, 80:3327-34.



- La Marca, A.; Bertucci, E.; Giulini, S.; Tirelli, A.; Malavasi, B.; Volpe, A. (2006):* Ovulation induction in anovulatory women. *Minerva Ginecol.* Dec;58(6):489-97.
- Lambert, A.; Rodgers, M.; Mitchell, R.; Wood, A.M.; Wardle, C.; Hilton, B. and Robertson, W.R. (1995):* In-vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP. *Hum. Reprod.*, 10, 1928-1935.
- Lean, M.E.J.; Han, T.S.; Durenberg, P. (1996):* Predicting body composition by densitometry from simple anthropometric measurement. *Am. J. Clin. Nutr.*, 63:4.
- Lee, O.; Farquhar, C.; Toomath, R.; Repson, R. (2000):* Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. *Cochrane Database Syst Rev.* 4:CD000194.
- Legro, R.S.; Barnhart, H.X.; Schlaff, W.D.; Carr, B.R.; Diamond, M.P.; Carson, S.A.; Steinkampf, M.P. (2007):* Clomiphene, metformin, or both for infertility in the



polycystic ovary syndrome. N Engl J Med., Feb 8;356(6):622-4.

Lonaye, E.; Vankrieken, L.; Depreester, S.; Pstti, J.; De Cooman, S. (2004): Agonists induced regulation of pituitary receptors for GnRH. J. Biol. Chem., 258:12002-12009.

Lord, J.M.; Flight, I.H.; Norman, R.J. (2003a): Metformin in polycystic ovary syndrome systemic review and meta-analysis. BMJ, 327:951-955.

Lord, J.M.; Flight, I.H.; Norman, R.J. (2003b): Insulin sensitising drugs (metformin troglitazone rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev., CD003053.

Loumaye, E.; Martineau, I.; Piazzzi, A.; O'Dea, L.; Ince, S.; Howles, C.; Decosterd, G.; Van Loon, K. and Galazka, A. (1996): Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Hum. Reprod., 11, 95-107.

Ludwig, M.; Doody, K.J.; Doody, K.M. (2003): Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil. Steril., 79:1051.



Manson, J.E.; Willett, W.C.; Stampfer, M.J.; Coddin, G.A.; Hunter, D.J.; Hankinson, S.E.; Hennekens, C.H.; Speizer, F.E. (1995): Body weight and mortality among women. *New Engl. J. Med.*, 333:677.

Martin, J.A.; Hamilton, B.E.; Sutton, P.D.; Ventura, S.J.; Menacker, F.; Munson, M.L. (2003): Births : final data for 2002 *Natl. Vital. Stat. Rep.*, 52:1.

Meldrum, D.R.; Wisot, A.; Hamilton, F.; Gutlay, A.L.; Huynh, D.; Kempton, W. (2005): Timing of initiation and dose schedule of leuprolide influence the time course of ovarian suppression. *Fertil. Steril.*, 50:400.

Michelmores, K.F.; Balen, A. H.; Dunger, D.B. and Vessey, M.P. (1999): Polycystic ovaries and associated clinical and biochemical features in young women. *Clinical Endocrinology (Oxford)*; 51:779-786.



- Mici, D.; Sumarac-Dumanovi, M.; Macut, D.J.; Kendereski, A.; Zoric, S.; Popovi, V.; Cvijovi, G.; Dieguez, C.; Casanueva, F.F. (2003):* Growth-hormone response to combined stimulation with GHRH plus GH-releasing peptide-6 in obese patients with polycystic ovary syndrome before and after short-term fasting. *J. Endocrinol. Invest.*, 26(4):333-40.
- Mitwally, F.M. and Casper, R.F. (2001):* Use of aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. *Fertil. Steril.*, 75:350-9.
- Moggetti, P.; Castello, R.; Negri, C.; Tosi, F.; Perrone, F.; Caputo, M. et al. (2000):* Metformin effects on clinical features, endocrine and metabolic profiles and insulin sensitivity in polycystic ovary syndrome : A randomized, double blind, placebo controlled 6 month trial, followed by open, long term clinical evaluation. *J. Clin. Endocrinol. Metab.*, 85:139-46.
- Morin-Papunen, L.C.; Kiviunen, R.M.; Ruukonen, A.; Martikainen, H.K. (1998):* Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in



References



women with polycystic ovary syndrome. *Fertil. Steril.*, 69:691-6.

Morin-Papunen, L.C.; Vauhkonen, I.; Koivunen, R.; Ruokonen, A.; Marti-kainen, H.; Tapanainen, J.S. (2003): Metformin versus ethinyl estradiol–cypro-terone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. *J. Clin. Endocrinol. Metab.*, 88:148–56.

Motta, T.; de Vincentiis, S.; Marchini, M.; Colombo, N.; D'Alborton, A. (1996): Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics, *Fertil. Steril.*, 65:440.

Muscelli, E.; Camastra, S.; Catalano, C.; Galvan, A.Q.; Clociaro, D.; Baidl and Ferranninl, E. (1997): Metabolic and cardiovascular assessment in moderate obesity effect of weight loss, *J. Clin. Endocrinol. Metab.*, 82:2937.

Musso, C.; Cochran, E.; Javor, E. Young, J.; Depaoli, A.M.; Gorden, P. (2005): The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary



function in male and female hypoleptinemic lipodystrophic patients.

National Institutes of Health (NIH) and National Heart Lung and Blood Institute (NHLBI) (1998): Clinical guidelines on the identification evaluation and treatment of overweight and obesity. The evidence report, US. Government printing Office, Washington, DC.

National Task Force on the Prevention and Treatment of Obesity (1996): Long term pharmacotherapy in the management of obesity. JAMA., 276:1907.

Nestler, J.E. (2002): Should patients with polycystic ovary syndrome be treated with metformin? An enthusiastic endorsement Human Reprod., 17:1950-3.

Nestler, J.M.; Stovall, D.; Akhter, N.; Iuorno, M.J.; Jakubowicz, D.J. (2002): Strategies for the use of insulin sensitizing drugs to :209-15. treat infertility in women with polycystic ovary syndrome. Fertil.. Steril.,

Ng, E.H.; Wat, N.M.; Ho, P.C. (2001): Effects of metformin on ovulation rate, hormonal and



References



metabolic profiles in women with clomiphene resistant polycystic ovaries : a randomized double blinded, placebo-controlled trial, Hum. Reprod., 16:1625.

Norman, R.J.; Mahabeer, S.; Masters, S. (1995): Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome. Fertil. Steril., 63:58.

Olive, D.L. (2005): The role of gonadotropins in ovulation induction. Am. J. Obstet. Gynecol., 172:759.

Padilla, S.L.; Smith, R.D.; Garcia, J.E. (2005): Lupron screening test: tailoring the use of leuprolide acetate in ovarian stimulation for in vitro fertilization. Fertil. Steril., 56:79-83.

Pakrasi, P.L. and Tiwari, A. (2006) : Ovulation induction by antiestrogens in an Indian tropical vespertilionid bat, *Scotophilus heathi*. Life Sci. 2006 Nov 2;79(23):2217-20.

Palomba, S.; Orio, F. Jr.; Falbo, A.; Russo, T.; Tolino, A.; Zullo, F. (2006): Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertil Steril. Dec; 86 (6): 1694-701.



- Papateo, E.; Doldi, N.; De Santis, L.; Marelli, G.; Marsiglio, E.; Rofena, S.; Ferrari, A. (2001):* Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. *Hum. Reprod.*, 16:2263.
- Park, Y.W.; Zhu, S.; Palaniappan, L.; Heshka, S.; Carnethon, M.R.; Heymsfield, S.B. (2003):* The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. *Arch. Intern. Med.*, 163:427.
- Parsanezhad, M.E.; Alborzi, S.; Motazedlan, S.; Omrani, G. (2002):* Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective double-blinded, placebo-controlled trial. *Fertil. Steril.*, 78:1001.
- Pasquali, R.; Gabineri, A.; Biscotti, D.; Vicennati, V.; Galiardi, L.; Colitta, D. et al. (2000):* Effect of long-term treatment with metformin added to hypocaloric diet on body



composition, fat distributio and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metabl., 85:2767-74.

Paul, S. and Carolin, O. (2004): Strategies for super ovulation for IVF. In good clinical practice in assisted reporduction (1st edition). Cambridge University Press, United Kingdom, pp. 112-129.

Pellicer, A.; Simon, C.; Miro, F.; Castellvi, R.M.; Ruiz, M.; Perez, M.; Bonilla-Musoles, F. (2005): Ovarian response and outcome of in vitro fertilization in patients treated with gonadotrophin releasing hormone analogues in different phases of the menstrual cycle. Hum. Reprod., 4:285.

Peter, R.B. (2006): Ultrasound in assisted conception. In Textbook of IVF and Assisted Reproduction. The Bourn guide to clinical and laboratory practice (1st edition). Taylor and Trancis (eds) in United Kingdom, pp. 93-107.

Rabe, T.; Diedrich, K.; Strowitzki, T. (2002): Manual on Assisted Reproduction (3rd ed.). In : Klaws Grunwald, Thomas Rabe and Blue Runnebaum;



Eds. Assessment of early embryo development.
Lippincott Raven, pp. 130-136.

Reddy, S.S.K. and Kahn, C.R. (1989): Epidermal growth factor receptor defect leprechaunism: a multiple growth factor resistant syndrome. *J. Clin. Endocrin.*, 84:1569.

Rich-Edwards, J.W.; Spiegelman, D.; Garland, M.; Hetzmark, E.; Hunter, D.J.; Colditz, G.A. et al. (2002): Physical activity, body mass index, and ovulatory disorder infertility. *Epidemiology*, 13:184-90.

Rizk, A.Y.; Bedaiwy, M.A.; Al-Inany, H.G. (2005) : N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. *Fertil. Steril.*, 83(2):367-70.

Ron EL-R, Chillik, C.F.; Itskovitz, J.; Hann, D.W.; McGuine, J.L.; Hogen, G.D. (2005): Characterizing pituitary response of a GnRH agonist in monkeys: tonic FSH/LH secretion versus acute GnRH challenge tests before, during and after treatment. *Fertil. Steril.*, 48:480-485.



References



- Salpeter, S.R.; Greyber, E.; Pasternak, G.A.; Salpeter, E.E. (2003):* Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus : systematic review and meta analysis. Arch. Intern. Med., 163:2594.
- Sampson, M.; Kong, C.; Patel, A.; Unwin, R.; Jacobs, H. (1996):* Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without polycystic ovary syndrome. Clin. Endocrinol, 45:623.
- Santoro, N.; Wierman, M.E.; Filicori, M.; Walds- treicher, J.; Crowley, W.F., Jr. (1986):* Intravenous administration of pulsatile gonadotropin releasing hormone in hypothalamic amenorrhea after of dosage. J. Clin. Endocrinol. Metab., 62:109.
- Schachter, M.; Friedler, S.; Raziel, A.; Strassburger, D.; Bern, O.; Ron-el, R. (2001):* Improvement of IVF outcome in poor responders by discontinuation of GnRH analogue during the gonadotropin stimulation phase- a function of improved embryo quality. J. Assist. reprod. Genet., 18:197.



- Schneider, D. and Sobel, B. (1996):* Synergistic augmentation of expression of PAI-1 induced by insulin, VLDL, and fatty acids. *Coronary Artery Dis.*, 7:813.
- Schwartz, M.W.; Seeley, R.J. (1997):* The new biology of body weight regulation. *J. Am. Diet. Assoc.*, 97:54.
- Scott, R.T.; Bertrand, E.; Clark, D.A.; Lee, S. (2005):* Ovarian hyperstimulation with ultrashort protocol GnRH agonist in poor responder. *Assist. Reprod. Genet*, 10:21-30.
- Sereepapong, W.; Suwajanakorn, S.; Triratanachai, S.; Sampatanukul, P.; Pruksananonda, K.; Boonkasemsantl, W.; Rehnprayoon, D. (2000):* Effects of clomiphene citrate on the endometrium of regularly cycling women, *Fertil. Steril.*, 73:287.
- Shaw, J.C. and White, L.E. (2002):* Long-term safety of spironolactone in acne: results of an 8-years followup study. *J. Cutan. Med. Surg.*, 6:541-545.
- Shoham, Z.; Zosmer, A.; Insler, V. (1999):* Early miscarriage and fetal malformations after induction of ovulation (by clomiphene citrate



References



and/or human menotropins), in vitro fertilization and gamete intrafallopian transfer. Fertil Steril., 55:1.

Sjöström, C.D.; Lissner, L.; Sjöström, L. (1997): Relationships between changes in body composition and changes in cardiovascular risk factors. The SOS Intervention Study. Obes. Res., 5:519.

Speroff, L. and Marc, A. (2005) : Ovary-embryology and development. In clinical gynecologic endocrinology and infertility, Seventh Edition. Lippincott William & Wilins, p. 98-109

Speroff, L.; Glass, R.H.; Kase, N.G. (1999): Anovulation and the polycystic ovary syndrome. Clinical gynecologic endocrinology and infertility. 6th ed. Baltimore: Williams and Wilkins, 487–521, 1105.

Speroff, L.; Glass, R.H; Kase, N.G. (1990): Hirsutism; clinical gynecologic endo-crinology and infertility. 6th ed. Baltimore: Williams and Wilkins, 523–50.

Spritzer, P.M.; Lisboa, K.O.; Mattiello, S.; Lhlhier, F. (2000): Spironolactone as a single agent



References



for long-term therapy of hirsute patients. Clin. Endocrinol. (Oxf), 52:587-594.

Stades, A.M.; Helkens, J.T.; Erkelens, D.W.; Holleman, F.; Hoekstra, J.B. (2004): Metformin and lactic acidosis : cause or coincidence? A review of case reports. J. Intern. Med., 255:179.

Stadtmauer, L.A.; Wong, B.C.; Oehninger, S. (2002): Should patients with poly-cystic ovary syndrome be treated with metformin? Human Reprod., 17:3016-25.

Stein, I.F. and Leventhal, M.L (1935): Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol., 29:181-91.

Stelling, J.R.; Chapman, E.T.; Frankfurter, D.; Harris, D.H.; Oskowits, S.P.; Reindollar, R.H (2003): Subcutaneous versus intramuscular administration of human chorionic gonadotropin during an in vitro fertilization cycle. Fertil. Steril., 79:881.

Surry, E.R.; Schoolcraft, W.B.; Kligman, I. (2004): Mini dose GnRH agonist versus conventional protocol in treatment of poor responder. Fertil. Steril., 73:667-676.



- Talbot, J.A.; Bricknell, E.J.; Rajkhowa, M.; Drook, A.; O'Rahilly, S. et al. (1996):* Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. *J. Clin. Endocrinol. Metab.*, 81:1979.
- Tan, W.C.; Yap, C.; Tan, A.S. (2001):* Clinical management of PCOS. *Acta Obstet. Gynecol. Scand.*, 80:689–96.
- Tarlatzis, B.C.; Grimbizis, G. (2002):* GnRH-agonist. In : Ovulation induction, 12:157-170.
- Techatraisak, K.; Conway, G.S.; Rumsby, G. (1997):* Frequency of a polymorphism in the regulatory region of the 17 α -hydroxylase-17,20-lyse (CYP17) gene in hyperandrogenic states. *Clin. Endocrinol.*, 46:131.
- The Rotterdam ESHRE/ASRM-Sponsored PCOS (2004):* Consensus Work-shop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil. Steril.*, 81:19–25.
- Thomas, A.E.; McKay, D.A.; Cutlip, M.B. (1976):* A nomograph method for assessing body weight, *Am. J. Clin. Nutr.*, 29:302.



- Timmerman-van Kessel, E.C.; Clkot, R.J.; Dargel-Donkers, E.J.; Zwertbroek, W.; van Dop, P.A.; Schoot, D.C. (2000):* A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin releasing hormone after gonadotropin releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome. *Fertil. Steril.*, 73:1145.
- Tureck, R.W.; Garcia, C.R.; Blasco, L.; Mastroianni, L.J. (2005):* Perioperative complications arising after transvaginal oocyte retrieval. *Obstet. Gynecol.*, 81:590.
- Udoff, I. and Adashi, E.Y. (1995):* Polycystic ovarian disease: A new look at an old subject. *Current Opinion in Obstetric Studies*; 7:340-3.
- Urbancsek, J.; Witthaus, E.; Wisot, A. (2005):* Mid-luteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization. *Fertil. Steril.*, 65:966.



References



- Urbanek, M.; Legro, R.S.; Driscoll, D.A.; Azziz, R.; Ehrmann, D.A.; Norman, R.; Strauss III J.F.; Spielman, R.S.; Dunaif, A. (1999):* Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. *Proc. Natl. Acad. Sci., USA*, 96:8573.
- Van de Weijer, B.H.; Mulders, J.W.; Bos, E.S.; Verhaert, P.D.; Van den Hooven, H.W. (2003):* Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities, *Reprod. Biomed Online.*, 7:547.
- van Welby, M.; Bayram, N.; and van der Veen (2003):* Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. *Human Reproduction*, Vol. 18, No. 6, pp. 1143-49.
- Vandermolen, D.T.; Ratts, V.S.; Evans, W.S.; Stovall, D.W.; Kauma, S.W.; Nestier, J.E. (2001):* Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic



References



ovary syndrome who are resistant to clomiphene citrate alone. *Fertil. Steril.*, 75:310.

Vital, Reyes, V.S.; Tellez Velasco, S.; Hinojoss Cruz, J.C.; Reyes Fuentes, A. (2000): Clomiphene acetate and prednisone : alternative approach for the management of patients with chronic anovulation and clomiphene treatment failure. *Ginecol. Obstet. Mex.*, 68:266.

Vrbikova, J.; Dvorakova, K.; Hill, M.; Starka, L. (2006): Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary. *Endocr Regul.* Dec;40(4):119-23.

Wallace, C.; Lalor, E.A.; Chik, C.L. (1993): Hepato-toxicity complicating flutamide treatment of hirsutism. *Am. Intern. Med.*, 119:1150.

Webltsch, M.; Hauner, H.; Heinze, E.; Bockmann, A.; Benz, R.; Mayer, H.; Teller, W. (1995): Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. *J. Clin. Endocrinol. Metab.*, 80:3469.

Webster, J.; Piscitelli, G.; Polli, A.; Ferrari, C.I.; Ismail, I.; Scanlon, M.F. for the



- Cabergoline Comparative Study Group (1994)*: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. *New Engl. J. Med.*, 331:904.
- Whelan, J.G.; 3rd, Vlahos, N.F. (2000)*: The ovarian hyperstimulation syndrome, *Fertil. Steril.*, 73:883.
- Whitaker, R.C.; Wright, J.A.; Pepe, M.S.; Seidel, K.D.; Dietz, W.H. (1997)*: Predicting obesity in young adulthood from childhood and parental obesity, *New Engl. J. Med.*, 337:869.
- Yarali, H.; Bukulmez, O. and Gurgan, T. (1999)*: Urinary follicle-stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective randomized study. *Fertil. Steril.*, 72, 276-281.
- Yki-Jarvinen, H.; Nikkila, K.; Makimattila, S. (1999)*: Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. *Drugs*, 58 (Suppl. 1):53-4.